Predictors of hospital readmission two years after coronary artery bypass grafting.

OBJECTIVE: To determine the clinical factors before, and in association with, coronary artery bypass grafting (CABG) that increase the risk of readmission to hospital in the first two years after surgery. PATIENTS: All patients in western Sweden who had CABG without simultaneous valve surgery between 1 June 1988 and 1 June 1991. METHODS: All patients who were readmitted to hospital were evaluated by postal inquiry and hospital records. RESULTS: A total of 2121 patients were operated on, of whom 2037 were discharged from hospital. Information regarding readmission was missing in four patients, leaving 2033 patients; 44% were readmitted to hospital. The most common reasons for readmission were angina pectoris and congestive heart failure. There were 12 independent significant predictors for readmission: clinical history (a previous history of either congestive heart failure or myocardial infarction, or CABG); acute operation; postoperative complications (time in intensive care unit greater than two days, neurological complications); clinical findings four to seven days after the operation (arrhythmia, systolic murmur equivalent to mitral regurgitation); medication four to seven days after the operation (antidiabetics, diuretics for heart failure, other antiarrhythmics (other than beta blockers, calcium antagonists, and digitalis), and lack of treatment with aspirin). CONCLUSION: 44% of patients were readmitted to hospital two years after CABG. The most common reasons for readmission were angina pectoris and congestive heart failure. Four clinical markers predicted readmission: clinical history; acute operation status; postoperative complications; and clinical findings and medication four to seven days after operation.

[1]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[2]  K. Hammermeister,et al.  Effect of coronary artery bypass grafting on subsequent hospitalization. , 1983, The American journal of cardiology.

[3]  Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. , 1995, European heart journal.

[4]  T. David,et al.  Current risk of coronary bypass for unstable angina. , 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  F. Loop,et al.  Rehospitalizations after coronary revascularization among Medicare beneficiaries. , 1993, The American journal of cardiology.

[6]  C. Jenkins,et al.  Hospital readmissions among survivors six months after myocardial revascularization. , 1985, JAMA.

[7]  F. Grover,et al.  Initial report of the Veterans Administration Preoperative Risk Assessment Study for Cardiac Surgery. , 1990, The Annals of thoracic surgery.

[8]  J. Herlitz,et al.  Ten-year mortality rate after development of acute myocardial infarction in relation to clinical history and observations during hospital stay: experience from the Göteborg metoprolol trial. , 1993, Coronary artery disease.

[9]  J. Manson,et al.  Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. , 1991, Annals of internal medicine.

[10]  J. Herlitz,et al.  Mortality during the two years after coronary artery bypass grafting in relation to perioperative factors and urgency of operation. , 1995, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  F. Harrell,et al.  The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. , 1989, JAMA.

[12]  L. Smith,et al.  Preoperative determinants of postoperative costs associated with coronary artery bypass graft surgery. , 1994, Circulation.

[13]  P. Vuorinen Obesity and the Heart , 1963, British medical journal.

[14]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[15]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[16]  A. Maggioni,et al.  Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. , 1993, Journal of the American College of Cardiology.